Invasive Fungal Infections

4
Pipeline Programs
5
Companies
7
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
1
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

U
MICAFUNGIN SODIUMApproved
micafungin
Unknown Company
Echinocandin Antifungal [EPC]intravenous2025

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Astellas
AstellasChina - Shenyang
2 programs
1
MicafunginPhase 31 trial
MicafunginN/A1 trial
Active Trials
NCT02678598Completed2,555Est. Aug 2015
NCT00048750Terminated104Est. Jun 2003
BP
Basilea PharmaceuticaSwitzerland - Allschwil
3 programs
1
1
fosmanogepixPhase 21 trial
APX001Phase 11 trial
Fosmanogepix solution for infusionN/A1 trial
Active Trials
NCT06433128Available
NCT05491733CompletedEst. Jun 2021
NCT04240886TerminatedEst. May 2022
GS
Gilead SciencesFOSTER CITY, CA
2 programs
PET-CTN/A1 trial
PET-CTN/A
Active Trials
NCT05688592Recruiting224Est. Dec 2024
Eagle Pharmaceuticals
Eagle PharmaceuticalsNJ - Woodcliff Lake
1 program
Amphotericin B Liposome for InjectionN/A1 trial
Active Trials
NCT06977490CompletedEst. Oct 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AstellasMicafungin
Basilea Pharmaceuticafosmanogepix
Basilea PharmaceuticaAPX001
Eagle PharmaceuticalsAmphotericin B Liposome for Injection
Gilead SciencesPET-CT
AstellasMicafungin

Clinical Trials (7)

Total enrollment: 2,883 patients across 7 trials

NCT00048750AstellasMicafungin

Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU

Start: Jan 2003Est. completion: Jun 2003104 patients
Phase 3Terminated
NCT04240886Basilea Pharmaceuticafosmanogepix

Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds

Start: Jan 2020Est. completion: May 2022
Phase 2Terminated
NCT05491733Basilea PharmaceuticaAPX001

A Bioequivalence Study of APX001 High-load and Low-load Tablets

Start: Mar 2021Est. completion: Jun 2021
Phase 1Completed
NCT06433128Basilea PharmaceuticaFosmanogepix solution for infusion

Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections

N/AAvailable
NCT06977490Eagle PharmaceuticalsAmphotericin B Liposome for Injection

Human Bioequivalence Study of Amphotericin B Liposome for Injection

Start: May 2025Est. completion: Oct 2025
N/ACompleted
NCT05688592Gilead SciencesPET-CT

Usefulness of PET-CT for Invasive Fungal Infection

Start: Apr 2023Est. completion: Dec 2024224 patients
N/ARecruiting
NCT02678598AstellasMicafungin

A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections

Start: Mar 2015Est. completion: Aug 20152,555 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 2,883 patients
5 companies competing in this space